KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Change in Cash (2016 - 2025)

Vertex Pharmaceuticals has reported Change in Cash over the past 17 years, most recently at $140.0 million for Q4 2025.

  • Quarterly results put Change in Cash at $140.0 million for Q4 2025, up 120.71% from a year ago — trailing twelve months through Dec 2025 was $515.6 million (up 108.89% YoY), and the annual figure for FY2025 was $515.6 million, up 108.89%.
  • Change in Cash for Q4 2025 was $140.0 million at Vertex Pharmaceuticals, up from -$34.2 million in the prior quarter.
  • Over the last five years, Change in Cash for VRTX hit a ceiling of $1.3 billion in Q4 2022 and a floor of -$4.6 billion in Q2 2024.
  • Median Change in Cash over the past 5 years was $252.8 million (2021), compared with a mean of -$45.1 million.
  • Biggest five-year swings in Change in Cash: skyrocketed 554.96% in 2022 and later tumbled 633.74% in 2024.
  • Vertex Pharmaceuticals' Change in Cash stood at $519.9 million in 2021, then surged by 156.78% to $1.3 billion in 2022, then plummeted by 155.75% to -$744.3 million in 2023, then rose by 9.19% to -$675.9 million in 2024, then soared by 120.71% to $140.0 million in 2025.
  • The last three reported values for Change in Cash were $140.0 million (Q4 2025), -$34.2 million (Q3 2025), and $296.6 million (Q2 2025) per Business Quant data.